Oruka Therapeutics names Todd Edwards Chief Commercial Officer, effective August 24, 2026
Oruka Therapeutics said Todd Edwards began work as its Chief Commercial Officer on August 24, 2026, under an offer letter dated July 22, 2026. Edwards previously held commercial roles at Arcutis Biotherapeutics and Incyte, and his pay package includes a $525,000 base salary, a 40% target bonus and equity grants. The appointment fills a senior commercial role, and the filing discloses the severance terms that apply if his employment ends.
Key points
- Base salary of $525,000 with a discretionary bonus targeted at 40% of base salary
- Stock option for 20,000 shares and RSUs for 100,000 shares, with 25% vesting on August 24, 2027
- Signing bonus of $200,000, payable within 30 days of starting employment
- Severance of 12 months' base salary without a change in control; 1.0 times base salary plus target bonus if termination occurs within three months before or 12 months after a change in control
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 24, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.